Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that carries out the development of novel therapies for the treatment and prevention of allergic conditions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Allergy Therapeutics' research and development (R&D) activities focuses on developing new therapies for allergy treatment and allergy prevention. The company’s product pipeline in clinical development includes vaccines for tree, grass and house dust mite, and peanut allergy vaccine in pre-clinical development. It is developing Grass MATA MPL, Birch MATA MPL and Ragweed MATA MPL in Phase III trials; Trees MATA MPL in Phase II trials; VLP Peanut in Phase I trials; and VLP vaccines outside allergy in pre-clinical trials. In FY2023, the company spent GBP20.1 million on its R&D activities, which as a percentage of revenue stood at 32.9%, and grew 28.5% YoY.